Locally Acting Budesonide-Loaded Solid Self-Microemulsifying Drug Delivery Systems (SMEDDS) for Distal Ulcerative Colitis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: DOVE Medical Press Country of Publication: New Zealand NLM ID: 101263847 Publication Model: eCollection Cited Medium: Internet ISSN: 1178-2013 (Electronic) Linking ISSN: 11769114 NLM ISO Abbreviation: Int J Nanomedicine Subsets: MEDLINE
    • Publication Information:
      Original Publication: Auckland : DOVE Medical Press,
    • Subject Terms:
      Colitis, Ulcerative*/drug therapy ; Budesonide*/pharmacokinetics ; Budesonide*/chemistry ; Budesonide*/administration & dosage ; Emulsions*/chemistry ; Drug Delivery Systems*/methods; Animals ; Rats ; Male ; Solubility ; Particle Size ; Polysorbates/chemistry ; Anti-Inflammatory Agents/chemistry ; Anti-Inflammatory Agents/pharmacokinetics ; Anti-Inflammatory Agents/administration & dosage ; Biological Availability ; Disease Models, Animal ; Rats, Sprague-Dawley ; Administration, Rectal ; Ethylene Glycols
    • Abstract:
      Background: Budesonide (BUD) is a BCS class II medication with poor water solubility and limited oral bioavailability. In this study, innovative solid self-microemulsifying drug delivery systems (BUD-SMEDDS) were developed for effective local management of distal ulcerative colitis (UC).
      Methods: Based on solubility and emulsification tests, the components of the self-microemulsifying drug delivery system (SMEDDS) were Capryol™ 90, Tween 80, and Transcutol HP. The impacts of BUD-SMEDDS ingredients (as inputs) on the average globule size (AGS), polydispersity index (PDI), and self-emulsification time (SET) as responses were investigated using the Box-Behnken design methodology. Solid rectal systems were then fabricated using the optimized values of SMEDDS components in Lutrol ® bases. The developed systems were evaluated for in vitro characteristics and in vivo efficacy using a rat colitis model.
      Results: For all responses, the greatest impact was attributed to the oil content of SMEDDS. An optimized BUD-SMEDDS with AGS of 33 ± 2.9 nm, PDI of 0.29 ± 0.03 and SET of 25 ± 2.5 s) was selected for rectal formulations. The developed formulations demonstrated acceptable physical characteristics and mucoadhesive abilities. Differential scanning calorimetric (DSC) analysis revealed the absence of BUD crystallinity in the SMEDDS formulations. The drug release patterns could be regulated by selecting the grade and composition of the incorporated Lutrols. Clinical and histopathological assessments revealed considerable improvements in animals treated with BUD-SMEDDS formulations.
      Conclusion: Overall findings confirmed the superior capability of solid SMEDDS as BUD carriers to manage distal colitis in tested animals.
      Competing Interests: The authors report no conflicts of interest in this work.
      (© 2024 Ali et al.)
    • References:
      Eur J Pharm Sci. 2016 Oct 10;93:233-43. (PMID: 27503459)
      Nat Rev Gastroenterol Hepatol. 2015 Sep;12(9):537-45. (PMID: 26284562)
      Pharmaceutics. 2019 Mar 19;11(3):. (PMID: 30893859)
      AAPS PharmSciTech. 2019 Aug 12;20(7):284. (PMID: 31407165)
      Int J Pharm. 2008 May 1;355(1-2):269-76. (PMID: 18242895)
      AAPS PharmSciTech. 2009;10(3):724-31. (PMID: 19479384)
      Pharmaceutics. 2018 Sep 12;10(3):. (PMID: 30213143)
      Gastroenterology. 1998 Sep;115(3):525-32. (PMID: 9721148)
      Pharmaceutics. 2022 Nov 24;14(12):. (PMID: 36559086)
      Biol Trace Elem Res. 2010 Jul;136(1):87-95. (PMID: 19774348)
      AAPS PharmSciTech. 2015 Jun;16(3):645-55. (PMID: 25501871)
      Curr Protoc Immunol. 2014 Feb 04;104:15.25.1-15.25.14. (PMID: 24510619)
      J Pharm Biomed Anal. 2006 Oct 11;42(4):474-9. (PMID: 16842962)
      Toxicology. 2020 Apr 30;436:152437. (PMID: 32169474)
      Eur J Pharm Sci. 2016 Oct 10;93:447-55. (PMID: 27590128)
      Pharm Res. 2012 Oct;29(10):2817-32. (PMID: 22371051)
      Pharmaceutics. 2022 Sep 12;14(9):. (PMID: 36145675)
      Int J Pharm. 2012 Apr 4;425(1-2):9-18. (PMID: 22266534)
      Drug Dev Ind Pharm. 2019 Jul;45(7):1193-1204. (PMID: 30983428)
      Expert Opin Drug Deliv. 2020 Apr;17(4):495-509. (PMID: 32067500)
      Sci Rep. 2017 Jun 20;7(1):3924. (PMID: 28634361)
      Int J Pharm. 2012 Jul 1;430(1-2):114-9. (PMID: 22503953)
      Pharmaceutics. 2023 Jun 07;15(6):. (PMID: 37376117)
      Dig Dis. 2009;27(4):542-9. (PMID: 19897972)
      Br J Gen Pract. 2018 Oct;68(675):497-498. (PMID: 30262630)
      AAPS J. 2009 Dec;11(4):771-8. (PMID: 19908147)
      Gastroenterology. 2015 Apr;148(4):740-750.e2. (PMID: 25644096)
      Adv Pharm Bull. 2021 Feb;11(2):286-294. (PMID: 33880350)
      Int J Pharm. 2016 Apr 11;502(1-2):70-9. (PMID: 26899977)
      Polymers (Basel). 2022 Mar 07;14(5):. (PMID: 35267877)
      Pharmaceutics. 2020 Dec 17;12(12):. (PMID: 33348692)
      J Pharm Biomed Anal. 2001 Jan;24(3):371-80. (PMID: 11199216)
      Gastroenterology. 2001 Aug;121(2):255-60. (PMID: 11487534)
      Gastroenterology. 2012 Nov;143(5):1218-1226.e2. (PMID: 22892337)
      AAPS PharmSciTech. 2008;9(3):924-30. (PMID: 18686039)
      J Pharm Pharmacol. 2013 Oct;65(10):1440-50. (PMID: 24028611)
      J Microencapsul. 2014;31(1):31-40. (PMID: 23834315)
      Pharm Dev Technol. 2011 Nov-Dec;16(6):627-36. (PMID: 20715905)
      Acta Biomater. 2020 Jul 1;110:37-67. (PMID: 32417265)
      Biomaterials. 2018 Dec;185:97-105. (PMID: 30236840)
      Eur J Pharm Sci. 2022 Jul 1;174:106159. (PMID: 35263632)
      J Crohns Colitis. 2017 Mar 01;11(3):305-313. (PMID: 27571771)
      AAPS PharmSciTech. 2019 Mar 7;20(3):137. (PMID: 30847607)
      Eur J Pharm Biopharm. 2009 Aug;72(3):539-45. (PMID: 19298857)
      J Pharm Sci. 2023 Dec;112(12):3197-3208. (PMID: 37777011)
      Int J Nanomedicine. 2019 Jul 05;14:4949-4960. (PMID: 31308665)
      Heliyon. 2021 Mar 15;7(3):e06439. (PMID: 33786387)
      Int J Biol Macromol. 2016 Mar;84:261-7. (PMID: 26708427)
      Polim Med. 2011;41(2):23-34. (PMID: 21866794)
      Drug Deliv Transl Res. 2019 Oct;9(5):945-955. (PMID: 30877627)
      Drug Dev Ind Pharm. 2020 May;46(5):751-761. (PMID: 32250181)
      Adv Pharm Bull. 2020 Jul;10(3):389-398. (PMID: 32665897)
      Commun Biol. 2023 Jun 16;6(1):647. (PMID: 37328528)
      Adv Drug Deliv Rev. 2000 Dec 6;45(1):89-121. (PMID: 11104900)
      AAPS PharmSciTech. 2009;10(1):69-76. (PMID: 19148761)
      Drug Dev Ind Pharm. 2008 Jul;34(7):744-52. (PMID: 18612913)
      Int J Pharm. 2008 Oct 1;362(1-2):2-9. (PMID: 18650038)
      Drug Deliv. 2014 Sep;21(6):412-35. (PMID: 24215334)
      Front Med (Lausanne). 2020 May 05;7:167. (PMID: 32432120)
      Eur J Pharm Biopharm. 2011 Oct;79(2):250-7. (PMID: 21550401)
      Int J Nanomedicine. 2016 Aug 05;11:3777-88. (PMID: 27540291)
      Pharmaceutics. 2021 Jan 18;13(1):. (PMID: 33477667)
      Acta Histochem. 2014 Jan;116(1):5-13. (PMID: 23706531)
      AAPS PharmSciTech. 2015 Jun;16(3):579-88. (PMID: 25391273)
      Aliment Pharmacol Ther. 2006 Jan 15;23(2):303-12. (PMID: 16393311)
      Nanotechnology. 2016 Sep 16;27(37):375101. (PMID: 27491690)
      Drug Dev Ind Pharm. 2021 Jun;47(6):977-989. (PMID: 34278910)
      Molecules. 2015 Nov 05;20(11):19936-46. (PMID: 26556328)
    • Contributed Indexing:
      Keywords: Box Behnken design; Budesonide; SMEDDS; Ulcerative colitis; efficacy
    • Accession Number:
      51333-22-3 (Budesonide)
      0 (Emulsions)
      0 (Polysorbates)
      A1A1I8X02B (carbitol)
      0 (Anti-Inflammatory Agents)
      0 (Ethylene Glycols)
    • Publication Date:
      Date Created: 20241119 Date Completed: 20241119 Latest Revision: 20241120
    • Publication Date:
      20241120
    • Accession Number:
      PMC11570536
    • Accession Number:
      10.2147/IJN.S484277
    • Accession Number:
      39558914